Deal Snapshot: The UK-based private equity firm will acquire troubled specialty pharma TherapeuticsMD for roughly $177m, after the company’s three-product portfolio yielded revenues of $85.8m in 2021.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced November through December 2013